Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | December 22, 2020 | December 28, 2020 |
| Lipocine Inc.LPCN · Entity 7696 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date December 22, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-12-22 | Direct | 754,839 |
Reported balance
After 2020-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-22 · Grant · Acquired 754,839 · Balance 754,839 |
Lipocine Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2036-06-03 | Direct | 13,290 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 1,764 · Balance 13,290 F1: 100% vesting one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vesting one year from date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $2.19 Strike: $2.19 | $3,863.16 |
DisclosureSEC source: 0001493152-26-027259 · ownership.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,290 Underlying: Common Stock · 1,764 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:07 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $3.20 Strike: $3.20 | $5,644.80 |
DisclosureSEC source: 0001641172-25-013796 · ownership.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,526 Underlying: Common Stock · 1,764 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:45 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $7.05 Strike: $7.05 | $12,436.20 |
DisclosureSEC source: 0001493152-24-023213 · ownership.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 1,764 shares Expires 2035-06-05 Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:35 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.27 Strike: $0.27 | $7,968.00 |
DisclosureSEC source: 0001493152-23-016690 · ownership.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-10 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 22:51 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon Stock | 4,000 | $0.34 | $1,360.00 |
DisclosureSEC source: 0001493152-23-008304 · ownership.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,125 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:36 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016406 · ownership.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:44 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000539 · doc4_7261.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:30 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 754,839 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0000899243-20-035201 · doc4.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,839 Underlying: Common Stock · 754,839 shares Expires 2030-12-22 Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 5,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000980 · doc4_6963.xml · derivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000980 · doc4_6963.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:10 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000591 · doc4_6753.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 13:02 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 1,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0000899243-20-009312 · doc4.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-03-20 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:10 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000609 · doc4_6153.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| February 03, 2019 Filed Feb 6, 2019 00:57 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 657,895 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0000899243-19-002715 · doc4.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,895 Underlying: Common Stock · 657,895 shares Expires 2029-02-03 Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:29 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStcck Optoin (right to buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000699 · doc4_5501.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 21:07 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 56,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007587 · doc4.xml · derivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2028-03-13 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 21:07 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 253,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007587 · doc4.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,000 Underlying: Common Stock · 253,000 shares Expires 2028-03-13 F1 · security: These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · derivative · entry 3 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common stock · 1,750 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon stock | 875 | $3.47 | $3,033.36 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · nonDerivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · derivative · entry 9 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F4 · derivative.expiration_date: The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · derivative · entry 8 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F3 · derivative.expiration_date: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · derivative · entry 7 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F2 · derivative.expiration_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Tax withholdingCommon Stock | 59,400 | $0.34 | $20,196.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 6 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,000 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 5 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Tax withholdingCommon Stock | 118,800 | $0.34 | $40,392.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 4 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,400 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 3 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Tax withholdingCommon Stock | 118,800 | $0.34 | $40,392.00 |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,200 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:39 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000126 · doc4_4501.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common stock · 7,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.